<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">

<pmc-articleset><article article-type="research-article" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink">
<!--The publisher of this article does not allow downloading of the full text in XML form.-->
<?properties manuscript?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-journal-id">9607835</journal-id>
<journal-id journal-id-type="pubmed-jr-id">20545</journal-id>
<journal-id journal-id-type="nlm-ta">Mol Psychiatry</journal-id>
<journal-id journal-id-type="iso-abbrev">Mol. Psychiatry</journal-id>
<journal-title-group>
<journal-title>Molecular psychiatry</journal-title>
</journal-title-group>
<issn pub-type="ppub">1359-4184</issn>
<issn pub-type="epub">1476-5578</issn>
</journal-meta>
<article-meta>
<article-id pub-id-type="pmid">29988084</article-id>
<article-id pub-id-type="pmc">6614015</article-id>
<article-id pub-id-type="doi">10.1038/s41380-018-0113-6</article-id>
<article-id pub-id-type="manuscript">NIHMS1017564</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title><italic>Shank3</italic> mutation in a mouse model of autism leads to
changes in the S-nitroso-proteome and affects key proteins involved in vesicle
release and synaptic function</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author" corresp="yes" equal-contrib="yes">
<name>
<surname>Amal</surname>
<given-names>Haitham</given-names>
</name>
<email>haitham.amal85@gmail.com</email>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author" equal-contrib="yes">
<name>
<surname>Barak</surname>
<given-names>Boaz</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Bhat</surname>
<given-names>Vadiraja</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Gong</surname>
<given-names>Guanyu</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Joughin</surname>
<given-names>Brian A.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A4">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Xin</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wishnok</surname>
<given-names>John S.</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Feng</surname>
<given-names>Guoping</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Tannenbaum</surname>
<given-names>Steven R.</given-names>
</name>
<email>srt@mit.edu</email>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="aff" rid="A5">5</xref>
</contrib>
</contrib-group>
<aff id="A1"><label>1</label>Department of Biological Engineering, Massachusetts
Institute of Technology, Cambridge, MA 02139, USA</aff>
<aff id="A2"><label>2</label>McGovern Institute for Brain Research, Massachusetts
Institute of Technology, Cambridge, MA 02139, USA</aff>
<aff id="A3"><label>3</label>Agilent Tech. Inc, Wilmington, DE 19808, USA</aff>
<aff id="A4"><label>4</label>Koch Institute for Integrative Cancer Research,
Massachusetts Institute of Technology, Cambridge, MA 02139, USA</aff>
<aff id="A5"><label>5</label>Department of Chemistry, Massachusetts Institute of
Technology, Cambridge, MA 02139, USA</aff>
<author-notes>
<fn fn-type="COI-statement" id="FN2">
<p id="P51"><bold>Conflict of interest</bold> The authors declare that they have no
conflict of interest.</p>
</fn>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>28</day>
<month>3</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>09</day>
<month>7</month>
<year>2018</year>
</pub-date>
<pub-date pub-type="ppub">
<month>8</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="pmc-release">
<day>01</day>
<month>8</month>
<year>2020</year>
</pub-date>
<volume>25</volume>
<issue>8</issue>
<fpage>1835</fpage>
<lpage>1848</lpage>
<!--elocation-id from pubmed: 10.1038/s41380-018-0113-6-->
<abstract id="ABS1">
<p id="P1">Mutation in the <italic>SHANK3</italic> human gene leads to different
neuropsychiatric diseases including Autism Spectrum Disorder (ASD), intellectual
disabilities and Phelan-McDermid syndrome. <italic>Shank3</italic> disruption in
mice leads to dysfunction of synaptic transmission, behavior, and development.
Protein S-nitrosylation, the nitric oxide (NO<sup>•</sup>)-mediated
posttranslational modification (PTM) of cysteine thiols (SNO), modulates the
activity of proteins that regulate key signaling pathways. We tested the
hypothesis that <italic>Shank3</italic> mutation would generate downstream
effects on PTM of critical proteins that lead to modification of synaptic
functions. SNO-proteins in two ASD-related brain regions, cortex and striatum of
young and adult InsG3680(+/+) mice (a human mutation-based
<italic>Shank3</italic> mouse model), were identified by an innovative mass
spectrometric method, SNOTRAP. We found changes of the SNO-proteome in the
mutant compared to WT in both ages. Pathway analysis showed enrichment of
processes affected in ASD. SNO-Calcineurin in mutant led to a significant
increase of phosphorylated Synapsin1 and CREB, which affect synaptic vesicle
mobilization and gene transcription, respectively. A significant increase of
3-nitrotyrosine was found in the cortical regions of the adult mutant, signaling
both oxidative and nitrosative stress. Neuronal NO<sup>•</sup> Synthase
(nNOS) was examined for levels and localization in neurons and no significant
difference was found in WT vs. mutant. S-nitrosoglutathione concentrations were
higher in mutant mice compared to WT. This is the first study on
NO<sup>•</sup>-related molecular changes and SNO-signaling in the
brain of an ASD mouse model that allows the characterization and identification
of key proteins, cellular pathways, and neurobiological mechanisms that might be
affected in ASD.</p>
</abstract>
</article-meta>
</front>
</article>
</pmc-articleset>